MZMike Zangenberg

Mike Zangenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mike Zangenberg has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia

    by Getnet Tesfaw, Dawd S. Siraj, Alemseged Abdissa, Rasmus Riemer Jakobsen, Øystein H. Johansen, Mike Zangenberg, Kurt Hanevik, Zeleke Mekonnen, Nina Langeland, Ola Bjørang, et al.

    Diarrhea claims >500,000 lives annually among children under five years of age in low- and middle-income countries. Mortality due to acute diarrhea (Escherichia spp., Campylobacter spp., and Streptococcus spp. Further, diarrhea cases are depleted in gut commensals such as Prevotella copri, Faecalibacterium prausnitzii, and Dialister succinatiphilus, with depletion being most pronounced in prolonged/persistent cases, suggesting that prolonged duration of diarrhea is accompanied by depletion of gut commensals and that re-establishing these via e.g., microbiota-directed food supplements offer a potential treatment strategy.


  • Open Access

    Imported leishmaniasis in Denmark

    by Mike Zangenberg, Marie Helleberg, Christen Rune Stensvold, Henrik Vedel Nielsen

  • Open Access

    Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study

    by Øystein H Johansen, Alemseged Abdissa, Mike Zangenberg, Zeleke Mekonnen, Beza Eshetu, Ola Bjørang, Yonas Alemu, Bizuwarek Sharew, Nina Langeland, Lucy J Robertson, et al.


  • Open Access

    Metronidazole-sensitive organisms in children with severe acute malnutrition: an evaluation of the indication for empiric metronidazole treatment

    by M. Zangenberg, A. Abdissa, Ø.H. Johansen, G. Tesfaw, T. Girma, J.A.L. Kurtzhals


  • Critical evaluation of the appetite test for children with severe acute malnutrition

    by Mike Zangenberg, Alemseged Abdissa, Øystein H. Johansen, Getnet Tesfaw, Henrik Friis, André Briend, Beza Eshetu, Jørgen A. L. Kurtzhals, Tsinuel Girma

    Objectives The appetite test is used to risk‐stratify for children with severe acute malnutrition (SAM) in in‐patient or out‐patient care. The test is recommended in guidelines despite lack of evidence. We evaluated its ability to identify children at risk of a poor treatment outcome. Methods We conducted an observational study of children diagnosed with SAM at three health facilities in Ethiopia. The appetite test was done independently, and the result did not affect decisions about hospitalisation and clinical care. Data were analysed using mixed linear and logistic regression models. Results Appetite was tested in 298 (89%) of 334 children enrolled; 56 (19%) passed. Children failing the appetite test had a 6·6% higher weight gain per day (95% CI 2·6, 10·8) adjusted for type of treatment, oedema, duration of follow up, and age than children passing the test. We found medical complications in 179 (54%) children. Medical complications were associated with blood markers of metabolic disturbance. Children with medical complications tended to have lower weight gain than those without complications (3·5%, 95%CI ‐0·25, 7·0). Neither the appetite test nor medical complications were correlated with bacteraemia or treatment failure. Conclusions Our findings question the use of the appetite test to identify children who need in‐patient care. An assessment of medical complications alone could be a useful risk indicator but needs to be evaluated in other settings.


  • Prolonged and persistent diarrhoea is not restricted to children with acute malnutrition: an observational study in Ethiopia

    by Mike Zangenberg, Øystein H. Johansen, Alemseged Abdissa, Beza Eshetu, Jørgen A. L. Kurtzhals, Henrik Friis, Halvor Sommerfelt, Nina Langeland, Kurt Hanevik

    Objectives To assess the prevalence of prolonged and persistent diarrhoea, to estimate their co-occurrence with acute malnutrition and association with demographic and clinical factors. Methods Case-control study where cases were children under 5 years of age with diarrhoea and controls were children without diarrhoea, frequency-matched weekly by age and district of residency. Controls for cases 0-11 months were recruited from vaccination rooms, and controls for cases 12-59 months were recruited by house visits using random locations in the catchment area of the study sites. Data were analysed by mixed model logistic regression. Results We enrolled 1134 cases and 946 controls. Among the cases, 967 (85%) had acute diarrhoea (AD), 129 (11%) had ProD and 36 (3.2%) had PD. More cases had acute malnutrition at enrolment (17% vs. 4%, P < 0.0001) and more were born prematurely (5.7% vs. 1.8%, P < 0.0001) than controls. About 75% of ProPD cases did not have acute malnutrition. Cases with AD and ProPD had different symptomatology, even beyond illness duration. Conclusions ProPD is common among children presenting with diarrhoea and is not confined to children with acute malnutrition. There is an urgent need for studies assessing causes of ProPD with and without acute malnutrition to develop treatment guidelines for these conditions.


  • Open Access

    Understanding biological mechanisms underlying adverse birth outcomes in developing countries: protocol for a prospective cohort (AMANHI bio–banking) study

    by Abdullah H Baqui, Rasheda Khanam, Mohammad Sayedur Rahman, Aziz Ahmed, Hasna Hena Rahman, Mamun Ibne Moin, Salahuddin Ahmed, Fyezah Jehan, Imran Nisar, Atiya Hussain, et al.

    The AMANHI study aims to seek for biomarkers as predictors of important pregnancy-related outcomes, and establish a biobank in developing countries for future research as new methods and technologies become available. AMANHI is using harmonised protocols to enrol 3000 women in early pregnancies (8-19 weeks of gestation) for population-based follow-up in pregnancy up to 42 days postpartum in Bangladesh, Pakistan and Tanzania, with collection taking place between August 2014 and June 2016. Urine pregnancy tests will be used to confirm reported or suspected pregnancies for screening ultrasound by trained sonographers to accurately date the pregnancy. Trained study field workers will collect very detailed phenotypic and epidemiological data from the pregnant woman and her family at scheduled home visits during pregnancy (enrolment, 24-28 weeks, 32-36 weeks & 38+ weeks) and postpartum (days 0-6 or 42-60). Trained phlebotomists will collect maternal and umbilical blood samples, centrifuge and obtain aliquots of serum, plasma and the buffy coat for storage. They will also measure HbA1C and collect a dried spot sample of whole blood. Maternal urine samples will also be collected and stored, alongside placenta, umbilical cord tissue and membrane samples, which will both be frozen and prepared for histology examination. Maternal and newborn stool (for microbiota) as well as paternal and newborn saliva samples (for DNA extraction) will also be collected. All samples will be stored at -80°C in the biobank in each of the three sites. These samples will be linked to numerous epidemiological and phenotypic data with unique study identification numbers. AMANHI biobank proves that biobanking is feasible to implement in LMICs, but recognises that biobank creation is only the first step in addressing current global challenges.


  • Open Access

    Childhood diarrhoeal deaths in seven low- and middle-income countries

    by Ahmed Ehsanur Rahman, Moinuddin, Mitike Molla, Alemayehu Worku, Lisa Hurt, Betty Kirkwood, Sanjana Brahmawar Mohan, Sarmila Mazumder, Zulfiqar Bhutta, Farrukh Raza, et al.

    To investigate the clinical characteristics of children who died from diarrhoea in low- and middle-income countries, such as the duration of diarrhoea, comorbid conditions, care-seeking behaviour and oral rehydration therapy use. The study included verbal autopsy data on children who died from diarrhoea between 2000 and 2012 at seven sites in Bangladesh, Ethiopia, Ghana, India, Pakistan, Uganda and the United Republic of Tanzania, respectively. Data came from demographic surveillance sites, randomized trials and an extended Demographic and Health Survey. The type of diarrhoea was classified as acute watery, acute bloody or persistent and risk factors were identified. Deaths in children aged 1 to 11 months and 1 to 4 years were analysed separately. The proportion of childhood deaths due to diarrhoea varied considerably across the seven sites from less than 3% to 30%. Among children aged 1-4 years, acute watery diarrhoea accounted for 31-69% of diarrhoeal deaths, acute bloody diarrhoea for 12-28%, and persistent diarrhoea for 12-56%. Among infants aged 1-11 months, persistent diarrhoea accounted for over 30% of diarrhoeal deaths in Ethiopia, India, Pakistan, Uganda and the United Republic of Tanzania. At most sites, more than 40% of children who died from persistent diarrhoea were malnourished. Persistent diarrhoea remains an important cause of diarrhoeal death in young children in low- and middle-income countries. Research is needed on the public health burden of persistent diarrhoea and current treatment practices to understand why children are still dying from the condition.


  • The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML

    by Mike Zangenberg, Lykke Grubach, Anni Aggerholm, Trine Silkjaer, Caroline Juhl‐Christensen, Charlotte Guldborg Nyvold, Eigil Kjeldsen, Hans Beier Ommen, Peter Hokland

    HOXA4 gene expression is a predictor for outcome in normal karyotypic acute myeloid leukaemia (AML) patients. Given that Meis1 is a co‐factor for Hox genes, we hypothesized that the combined expression of HOXA4 and MEIS1 might add prognostic information in these patients. When diagnostic samples from 246 AML patients were divided into three main groups based on gene expression levels of HOXA4 combined with MEIS1 we found that within the group of patients exhibiting low levels of HOXA4, those with a high expression of MEIS1 had a significantly worse outcome than those exhibiting low MEIS1 expression (P = 0.025). Moreover, this prediction was independent of cytogenetics, mutational status of the NPM1 and FLT3 genes as well as upon WBC and age. To evaluate the possible contribution of regulatory events underlying these observations, 157 patient samples were subjected to promoter hypermethylation analysis. We observed that 77% were HOXA4‐ and 15%MEIS1 hypermethylated and that this epigenetic alteration was highly correlated to the gene expression level (MEIS1: P = 0.001; HOXA4: P = 0.007). Finally, we found a higher expression level and a higher frequency of hypermethylation of HOXA4 among patients with NPM1 mutations. In conclusion, our data show that the combination of low HOXA4 and low MEIS1 gene expression is a favourable predictor for outcome in all AML patients and that the expression levels are governed by the methylation state of these genes.